Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men

Johan Onslev; Glenn A Jacobson; Christian K Narkowicz; Vibeke Backer; Anders Kalsen; Michael Kreiberg; Søren Jessen; Jens Bangsbo; Morten Hostrup

doi:10.1007/s00421-017-3679-9

Beta₂-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men

Johan Onslev, Glenn A Jacobson, Christian K Narkowicz, Vibeke Backer, Anders Kalsen, Michael Kreiberg, Søren Jessen, Jens Bangsbo, Morten Hostrup

10 Citations (Scopus)

Abstract

Purpose: β₂-Agonists have been proposed as weight-loss treatment, because they elevate energy expenditure. However, it is unknown what effect β₂-agonists have on energy expenditure in overweight individuals. Furthermore, the influence of β₂-agonist R- and S-enantiomer ratio for the increased energy expenditure is insufficiently explored.

Methods: Nineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22.7 (±2.1)%. On separate days, subjects received either placebo or inhaled racemic (rac-) formoterol (2 × 27 µg). After an overnight fast, energy expenditure and substrate oxidation were estimated by indirect calorimetry at rest and during submaximal exercise. Plasma (R,R)- and (S,S)-formoterol enantiomer levels were measured by ultra-performance liquid chromatograph-mass spectrometry.

Results: At rest, energy expenditure and fat oxidation were 12% (P ≤ 0.001) and 38% (P = 0.006) higher for rac-formoterol than placebo. Systemic (R,R):(S,S) formoterol ratio was correlated with change in energy expenditure at rest in response to rac-formoterol (r = 0.63, P = 0.028), whereas no association was observed between fat percentage and rac-formoterol-induced change in energy expenditure. During exercise, energy expenditure was not different between treatments, although carbohydrate oxidation was 15% higher (P = 0.021) for rac-formoterol than placebo. Rac-formoterol-induced shift in substrate choice from rest to exercise was related to plasma ln-rac-formoterol concentrations (r = 0.75, P = 0.005).

Conclusion: Selective β₂-adrenoceptor agonism effectively increases metabolic rate and fat oxidation in overweight individuals. The potential for weight loss induced by β₂-agonists may be greater for R-enantiopure formulations.

Original language	English
Journal	European Journal of Applied Physiology
Volume	117
Issue number	9
Pages (from-to)	1907-1915
Number of pages	9
ISSN	1439-6319
DOIs	https://doi.org/10.1007/s00421-017-3679-9
Publication status	Published - 1 Sept 2017

Keywords

Sympathomimetics
Substrate choise
Adrenergic
Energy consumption
Respiratory exchange

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00421-017-3679-9

Cite this

@article{e341784a622c472d95bb1963e6370d00,

title = "Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men",

abstract = "Purpose: β2-Agonists have been proposed as weight-loss treatment, because they elevate energy expenditure. However, it is unknown what effect β2-agonists have on energy expenditure in overweight individuals. Furthermore, the influence of β2-agonist R- and S-enantiomer ratio for the increased energy expenditure is insufficiently explored.Methods: Nineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22.7 (±2.1)%. On separate days, subjects received either placebo or inhaled racemic (rac-) formoterol (2 × 27 µg). After an overnight fast, energy expenditure and substrate oxidation were estimated by indirect calorimetry at rest and during submaximal exercise. Plasma (R,R)- and (S,S)-formoterol enantiomer levels were measured by ultra-performance liquid chromatograph-mass spectrometry.Results: At rest, energy expenditure and fat oxidation were 12% (P ≤ 0.001) and 38% (P = 0.006) higher for rac-formoterol than placebo. Systemic (R,R):(S,S) formoterol ratio was correlated with change in energy expenditure at rest in response to rac-formoterol (r = 0.63, P = 0.028), whereas no association was observed between fat percentage and rac-formoterol-induced change in energy expenditure. During exercise, energy expenditure was not different between treatments, although carbohydrate oxidation was 15% higher (P = 0.021) for rac-formoterol than placebo. Rac-formoterol-induced shift in substrate choice from rest to exercise was related to plasma ln-rac-formoterol concentrations (r = 0.75, P = 0.005).Conclusion: Selective β2-adrenoceptor agonism effectively increases metabolic rate and fat oxidation in overweight individuals. The potential for weight loss induced by β2-agonists may be greater for R-enantiopure formulations.",

keywords = "Sympathomimetics, Substrate choise, Adrenergic, Energy consumption, Respiratory exchange",

author = "Johan Onslev and Jacobson, {Glenn A} and Narkowicz, {Christian K} and Vibeke Backer and Anders Kalsen and Michael Kreiberg and S{\o}ren Jessen and Jens Bangsbo and Morten Hostrup",

note = "CURIS 2017 NEXS 202",

year = "2017",

month = sep,

day = "1",

doi = "10.1007/s00421-017-3679-9",

language = "English",

volume = "117",

pages = "1907--1915",

journal = "European Journal of Applied Physiology",

issn = "1439-6319",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men

AU - Onslev, Johan

AU - Jacobson, Glenn A

AU - Narkowicz, Christian K

AU - Backer, Vibeke

AU - Kalsen, Anders

AU - Kreiberg, Michael

AU - Jessen, Søren

AU - Bangsbo, Jens

AU - Hostrup, Morten

N1 - CURIS 2017 NEXS 202

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: β2-Agonists have been proposed as weight-loss treatment, because they elevate energy expenditure. However, it is unknown what effect β2-agonists have on energy expenditure in overweight individuals. Furthermore, the influence of β2-agonist R- and S-enantiomer ratio for the increased energy expenditure is insufficiently explored.Methods: Nineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22.7 (±2.1)%. On separate days, subjects received either placebo or inhaled racemic (rac-) formoterol (2 × 27 µg). After an overnight fast, energy expenditure and substrate oxidation were estimated by indirect calorimetry at rest and during submaximal exercise. Plasma (R,R)- and (S,S)-formoterol enantiomer levels were measured by ultra-performance liquid chromatograph-mass spectrometry.Results: At rest, energy expenditure and fat oxidation were 12% (P ≤ 0.001) and 38% (P = 0.006) higher for rac-formoterol than placebo. Systemic (R,R):(S,S) formoterol ratio was correlated with change in energy expenditure at rest in response to rac-formoterol (r = 0.63, P = 0.028), whereas no association was observed between fat percentage and rac-formoterol-induced change in energy expenditure. During exercise, energy expenditure was not different between treatments, although carbohydrate oxidation was 15% higher (P = 0.021) for rac-formoterol than placebo. Rac-formoterol-induced shift in substrate choice from rest to exercise was related to plasma ln-rac-formoterol concentrations (r = 0.75, P = 0.005).Conclusion: Selective β2-adrenoceptor agonism effectively increases metabolic rate and fat oxidation in overweight individuals. The potential for weight loss induced by β2-agonists may be greater for R-enantiopure formulations.

AB - Purpose: β2-Agonists have been proposed as weight-loss treatment, because they elevate energy expenditure. However, it is unknown what effect β2-agonists have on energy expenditure in overweight individuals. Furthermore, the influence of β2-agonist R- and S-enantiomer ratio for the increased energy expenditure is insufficiently explored.Methods: Nineteen males were included in the study of which 14 completed. Subjects were 31.6 (±3.5) years [mean (±95% CI)] and had a fat percentage of 22.7 (±2.1)%. On separate days, subjects received either placebo or inhaled racemic (rac-) formoterol (2 × 27 µg). After an overnight fast, energy expenditure and substrate oxidation were estimated by indirect calorimetry at rest and during submaximal exercise. Plasma (R,R)- and (S,S)-formoterol enantiomer levels were measured by ultra-performance liquid chromatograph-mass spectrometry.Results: At rest, energy expenditure and fat oxidation were 12% (P ≤ 0.001) and 38% (P = 0.006) higher for rac-formoterol than placebo. Systemic (R,R):(S,S) formoterol ratio was correlated with change in energy expenditure at rest in response to rac-formoterol (r = 0.63, P = 0.028), whereas no association was observed between fat percentage and rac-formoterol-induced change in energy expenditure. During exercise, energy expenditure was not different between treatments, although carbohydrate oxidation was 15% higher (P = 0.021) for rac-formoterol than placebo. Rac-formoterol-induced shift in substrate choice from rest to exercise was related to plasma ln-rac-formoterol concentrations (r = 0.75, P = 0.005).Conclusion: Selective β2-adrenoceptor agonism effectively increases metabolic rate and fat oxidation in overweight individuals. The potential for weight loss induced by β2-agonists may be greater for R-enantiopure formulations.

KW - Sympathomimetics

KW - Substrate choise

KW - Adrenergic

KW - Energy consumption

KW - Respiratory exchange

U2 - 10.1007/s00421-017-3679-9

DO - 10.1007/s00421-017-3679-9

M3 - Journal article

C2 - 28702809

SN - 1439-6319

VL - 117

SP - 1907

EP - 1915

JO - European Journal of Applied Physiology

JF - European Journal of Applied Physiology

IS - 9

ER -